FREE SHIPPING ON ORDERS OVER $300 – PLUS A FREE GIFT WITH EVERY AUGUST PURCHASE – THANK YOU FOR YOUR SUPPORT
FREE SHIPPING ON ORDERS OVER $300 – PLUS A FREE GIFT WITH EVERY AUGUST PURCHASE – THANK YOU FOR YOUR SUPPORT
$200.00
Amino Acid Sequence:
D‑Arg–Dmt–Lys–Phe–NH₂
Chemical Formula:
C₃₀H₄₇N₉O₅
CAS Registry Number:
736992-21-5
Primary mitochondrial myopathies (PMM)
Barth syndrome
Age‑related muscle decline (sarcopenia)
Cardiac disease & ischemia‑reperfusion injury
Ophthalmology (e.g., dry AMD)
Neurodegenerative and neuromuscular conditions
Systemic metabolic and inflammatory stress
Cardiolipin binding & cristae stabilization
Enhanced electron transport & ATP production
Reduction of ROS formation at the source
Protection from mitochondrial permeability transition
Improved mitochondrial membrane potential & dynamics
SS‑31 is now an FDA‑approved therapy for Barth syndrome and the first mitochondria‑targeted drug ever approved. Beyond this, it remains in active Phase 3 development for mitochondrial myopathy and dry AMD, with a broad pipeline exploring neuromuscular, cardiac, and neurodegenerative indications. Its mechanism—cardiolipin stabilization and mitochondrial restoration—is now clinically validated.
1.Tung C, Varzideh F, Farroni E, Mone P, Kansakar U, Jankauskas SS, Santulli G. Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. Int J Mol Sci. 2025 Jan 23;26(3):944.
2. Sabbah HN. Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid. Heart Fail Rev. 2022 Sep;27(5):1911-1923.
3. Sabbah HN, Alder NN, Sparagna GC, Bruce JE, Stauffer BL, Chao LH, Pitceathly RDS, Maack C, Marcinek DJ. Contemporary insights into elamipretide’s mitochondrial mechanism of action and therapeutic effects. Biomed Pharmacother. 2025 Jun;187:118056.
4. Karaa A, Bertini E, Carelli V, Cohen BH, Enns GM, Falk MJ, Goldstein A, Gorman GS, Haas R, Hirano M, Klopstock T, Koenig MK, Kornblum C, Lamperti C, Lehman A, Longo N, Molnar MJ, Parikh S, Phan H, Pitceathly RDS, Saneto R, Scaglia F, Servidei S, Tarnopolsky M, Toscano A, Van Hove JLK, Vissing J, Vockley J, Finman JS, Brown DA, Shiffer JA, Mancuso M; MMPOWER-3 Trial Investigators. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. 2023 Jul 18;101(3):e238-e252.
5. Thompson WR, Manuel R, Abbruscato A, Carr J, Campbell J, Hornby B, Vaz FM, Vernon HJ. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med. 2024 Jul;26(7):101138.
6. Zhang H, Chen Y, Li F, Wu C, Cai W, Ye H, Su H, He M, Yang L, Wang X, Zhou K, Ni W. Elamipretide alleviates pyroptosis in traumatically injured spinal cord by inhibiting cPLA2-induced lysosomal membrane permeabilization. J Neuroinflammation. 2023 Jan 7;20(1):6.
7. Nhu NT, Xiao SY, Liu Y, Kumar VB, Cui ZY, Lee SD. Neuroprotective Effects of a Small Mitochondrially-Targeted Tetrapeptide Elamipretide in Neurodegeneration. Front Integr Neurosci. 2022 Jan 17;15:747901.
CURRENT BATCH LOT NUMBER:
S2502026-06-05
CERTIFICATE OF ANALYSIS – TGMPURE SS31 50 mg (S2502026-06-05)
SS‑31 (Elamipretide) is a synthetic mitochondria‑targeted tetrapeptide (D‑Arg‑Dmt‑Lys‑Phe‑NH₂) engineered to selectively bind cardiolipin, a phospholipid essential for maintaining mitochondrial cristae structure, electron‑transport‑chain (ETC) integrity, and cellular bioenergetics. Unlike traditional antioxidants or metabolic modulators, SS‑31 acts directly at the inner mitochondrial membrane, stabilizing cardiolipin–protein interactions and restoring mitochondrial efficiency under conditions of oxidative, metabolic, or ischemic stress.
Over the past decade, SS‑31 has emerged as one of the most clinically advanced mitochondrial therapeutics. Research from the 2010s–2020s demonstrates its ability to improve ATP production, reduce ROS formation at the source, preserve mitochondrial membrane potential, and protect tissues from ischemia‑reperfusion injury. These effects translate into measurable improvements in muscle performance, cardiac function, neuromuscular resilience, and mitochondrial disease biomarkers.
In 2025, Elamipretide became the first FDA‑approved mitochondria‑targeted therapy, marking a major milestone in mitochondrial medicine. Beyond its approved indication, SS‑31 continues to be evaluated in primary mitochondrial myopathies, dry age‑related macular degeneration, heart failure, and age‑related muscle decline, positioning it as a foundational molecule in next‑generation metabolic and mitochondrial therapeutics.
QUANTITY: 50 MG
